Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | SHBG | P04278 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8094950 | 0.87 | ALDH1A1 (0.37) | GABRA1GABRB2CLCN2ALDH1A1ALOX15 | |
| SCHEMBL8095512 | 0.84 | BID (0.42) | ALOX15TSHRHTTHSD17B10CYP3A4 | |
| SCHEMBL28708772 | 0.83 | GABRA1 (0.48) | GABRA1GABRB2CLCN2ALDH1A1TSHR | |
| SCHEMBL8087557 | 0.83 | BID (0.48) | ALOX15HSD17B10 | |
| SCHEMBL2300929 | 0.83 | ALDH1A1 (0.50) | ALDH1A1ALOX15TSHRLMNAHPGD | |
| SCHEMBL622225 | 0.82 | CLCN2 (0.54) | GABRA1GABRB2CLCN2ALDH1A1ALOX15 | |
| Benzene SCHEMBL28861692 | 0.82 | CLCN2 (0.54) | GABRA1GABRB2CLCN2ALDH1A1ALOX15 | |
| SCHEMBL13862488 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2CLCN2ALDH1A1TSHR | |
| SCHEMBL8820704 | 0.82 | GABRA1 (0.46) | GABRA1GABRB2CLCN2ALDH1A1ALOX15 | |
| SCHEMBL8095850 | 0.81 | BID (0.50) | ALOX15HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3219204-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | INTREXON CORP (US) | 2017-11-30 | — | — | US | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3219204-A1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | Intrexon Corporation (US) | 2017-09-20 | — | — | EP | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| EP-3000317-B1 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2017-07-12 | — | — | EP | disclosed |
| CN-102776218-B | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system | 因特莱克森公司 | 2017-04-12 | — | — | CN | disclosed |
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2008-06-19 | — | — | US | disclosed |
| EP-1744619-A4 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | INTREXON CORP (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1744619-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RheoGene, Inc. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | INTREXON CORPORATION | 2005-12-01 | — | — | US | disclosed |
| WO-2005108617-A2 | MUTANT RECEPTORS AND THEIR USE IN A NUCLEAR RECEPTOR-BASED INDUCIBLE GENE EXPRESSION SYSTEM | RHEOGENE,INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-0708077-B1 | Diamino compounds and methods for preparing them | CHISSO CORP (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-5663440-A | Diamino compounds and methods for preparing them | CHISSO CORPORATION (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0708077-A1 | Diamino compounds and methods for preparing them | CHISSO CORPORATION (JP) | 1996-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080145935-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | GABRA1 991/4885GABRB2 1085/4885CLCN2 4208/4885 |
| US-20050266457-A1 | Modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms | NR2E3, HAVCR2, FCER2 | GABRA1 991/4885GABRB2 1085/4885CLCN2 4208/4885 |
| US-20170342440-A1 | Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System | NR2E3, NR1H4, NR5A2 | GABRA1 587/4885GABRB2 603/4885CLCN2 4647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.